Vitiligo
Conditions
Interventions
active group:None.
stable group:None.
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. the patients with clinical dermatologist specialist physical examination in one or several limitations of the body appear a disfiguring spot, Wood, light and white spot bright white fluorescent, diagnosed with vitiligo.Progress judge: reference vitiligo disease activity score (VIDA), clinical features, image with reaction, Wood lamp test results (1) VIDA integral score > 1 point for progress, namely 4 or higher phase is divided into rapid progress; (2) clinical features: a skin edge blur, inflammatory vitiligo, vitiligo in three color, white spot or confetti samples decreased pigment spots, such as clinical manifestations, progress can be judged to be vitiligo; (3) isomorphic reaction: white patches within 1 year skin injury, damage mode can be physical, chemical, etc.; (4) Wood lamp inspection results: boundary owes qing, Wood light skin lesion area > visual area, tips for progress. Article 4 above conform to any one can consider disease progression. Stability to determine: (1) VIDA to 0 points; (2) clinical features: a white spot in porcelain white, edge clear or pigmentation; (3) no isomorphic response (1 year) or higher; (4) Wood lamp: skin color is white, the boundary is clear, Wood skin lesion area or less visual area below the light.Comply with article 4 above at least two can prompt stability.Can also refer to the laser confocal scanning microscope and skin mirror image changes, auxiliary diagnosis; 2. aged 18 to 65 years; 3. into the group did not receive within six months before the treatment such as systemic corticosteroids, immune modulators; 4. and voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: (1) no pigmented nevus, pityriasis alba, inflammation, decreased after the pigment spots, mottled disease, idiopathic decreased pigment spots and anemia and other pigmented skin diseases; (2) with severe hypertension, diabetes, (3) active peptic ulcer disease, infections; (4) fracture, trauma repair and (or) with a clear history of osteoporosis; (5) with severe lung disease, liver and kidney function is not complete, coagulation can red blood disorders and (or) tumor;Mental illness (6) to the merger; (7) of pregnancy and/or lactation women; (8) to participate in other clinical researchers recently.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CXCL10;CCL20;tissue resident memory T cells;IFN-gama;sCD25;sCD27; | — |
Countries
China
Contacts
Public ContactLeihong Xiang
Huashan Hospital, Fudan University
Outcome results
None listed